Revelation Biosciences, Inc. (REVBW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 15Jul 20Jul 23Jul 29Aug 11Aug 14Aug 20Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.0x

Market Cap

$40352.00

MomentumView details →

1D Return

−2.99%

YTD Return

−18.75%

RSI (14)

43.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.0x

Market Cap

$40352.00

RSI (14)

43.8

MomentumView details →

1D Return

−2.99%

YTD Return

−18.75%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−106.79%

ROA (TTM)

−86.02%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+74.53%

FCF YoY

+46.72%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+72.68%

EBITDA YoY

−34.97%

EarningsView details →

EPS (Actual)

−$0.87

EPS Surprise

0.57%

Beats (12Q)

2/12

Next Q EPS Est

−$0.81

Avg Surprise (4Q)

19.18%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

6.21x

Quick Ratio

6.21x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−10.75M

Op. CF (TTM)

−9.33M

Next earningsNov 5, 2026 →

Latest newsMore news →

Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini in patients with acute kidney injury.17d ago

Revelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.17d ago

Similar companies

SeaStar Medical Holding CorporationICUCW Coeptis Therapeutics Holdings, Inc.COEPW Celularity Inc.CELUW Pasithea Therapeutics Corp.KTTAW Carisma Therapeutics, Inc.CARM Cardio Diagnostics Holdings, Inc.CDIOW Find similar companies →

Latest newsMore news →

Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 TITAN study evaluating Gemini in patients with acute kidney injury.17d ago Revelation Biosciences, Inc. granted restricted stock awards to CEO James Rolke and CFO Chester S. Zygmont III as part of their compensation.17d ago